



Pharmacy Prior Approval Request for Antiparkinson's Agents-Inbrija and Ongentys

Beneficiary Information

1. Beneficiary Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_
3. Beneficiary ID #: \_\_\_\_\_ 4. Beneficiary Date of Birth: \_\_\_\_\_ 5. Beneficiary Gender: \_\_\_\_\_

Prescriber Information

6. Prescribing Provider NPI #: \_\_\_\_\_
7. Requester Contact Information - Name: \_\_\_\_\_ Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_

Drug Information

8. Drug Name: \_\_\_\_\_ 9. Strength: \_\_\_\_\_ 10. Quantity Per 30 Days: \_\_\_\_\_
11. Length of Therapy (in days): [ ] up to 30 Days [ ] 60 Days [ ] 90 Days [ ] 120 Days [ ] 180 Days [ ] 365 Days

Clinical Information

Inbrija - initial authorization requests \*\*Initial requests can be approved for up to 6 months\*\*:
1. Is the beneficiary age 18 or older? [ ] Yes [ ] No
2. Does the beneficiary have a diagnosis of Parkinson's Disease and is experiencing "off" episodes? [ ] Yes [ ] No
3. Will the beneficiary be concurrently receiving optimized carbidopa/levodopa therapy? [ ] Yes [ ] No
4. Is the beneficiary currently taking a nonselective monoamine (MAO) inhibitor or has the beneficiary taken a MAO inhibitor within the last two weeks? [ ] Yes [ ] No
5. Does the beneficiary have asthma, COPD or other chronic lung disease? [ ] Yes [ ] No
Inbrija - reauthorization requests (please answer questions 1-6) \*\*Reauthorization requests can be approved for up to 12 months\*\*:
6. Has documentation been submitted that indicates the beneficiary has had an improvement in their symptoms from baseline? [ ] Yes [ ] No
Ongentys - initial authorization requests \*\*Initial requests can be approved for up to 6 months\*\*:
7. Is the beneficiary age 18 years of age or older? [ ] Yes [ ] No
8. Does the beneficiary have a diagnosis of Parkinson's Disease and is experiencing "off" episodes for at least 1.5 hours/day on average? [ ] Yes [ ] No
9. Does the beneficiary have no contraindications including ESRD (creatinine clearance <15 ml/min/1.73m2)? [ ] Yes [ ] No
10. Does the beneficiary have no contraindications including severe hepatic impairment (Child-Pugh C)? [ ] Yes [ ] No
11. Is the beneficiary currently taking a nonselective monoamine oxidase-B (MAO-B) inhibitor? [ ] Yes [ ] No
12. Will the beneficiary be concurrently receiving optimized carbidopa/levodopa therapy? [ ] Yes [ ] No
13. Has the beneficiary had an adequate trial and subsequent failure of at least 2 preferred adjunctive therapies (e.g., dopamine agonists, MAO-B inhibitors, catechol-O-methyltransferase [COMT] inhibitors) to control "off" symptoms? [ ] Yes [ ] No
Ongentys - reauthorization requests (please answer questions 7-15) \*\*Reauthorization requests can be approved for up to 12 months\*\*:
14. Has documentation been submitted that indicates the beneficiary has had clinically meaningful response to treatment (e.g., beneficiary shows a reduction in time of "off" episodes)? [ ] Yes [ ] No
15. Has the beneficiary experienced toxicity or treatment related adverse event from the drug (e.g., dyskinesias, hallucinations/psychotic behavior, impulse control/compulsive behaviors)? [ ] Yes [ ] No

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_
(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to (833) 404-2393

Pharmacy PA Call Center: (833) 585-4309

https://www.covermy meds.com/main/prior-authorization-forms/